A few days ago，Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has successfully obtained the “radiation safety license”. By this point of time，Guangdong Sinotau Molecular Imaging Technology Co., Ltd. has formally possessed the qualification of cyclotron operation and the production, use and sales of nuclides, which also creates the conditions for the smooth promotion of the company's subsequent R&D, production and operation of radioactive precision diagnostic and therapeutic drugs.

Guangdong Sinotau Molecular Imaging Technology Co., Ltd.，the radiopharmaceutical R&D and production base of Sinotau in South China, mainly engaged in the R&D, production, and promotion and sales of innovative radioactive precision diagnostic and therapeutic drugs. At present, the construction of the base is basically completed. The cyclotron built in the first phase of the project can commercially produce a variety of positron nuclides such as ¹⁸F, ⁶⁸Ga, ⁶⁴Cu, ⁸⁹Zr, etc. The R&D laboratory and the GMP production workshop of radiopharmaceuticals can engage in the R&D experiment and production of a variety of radionuclide-labeled diagnostic and therapeutic drugs.